← All Seres Therapeutics, INC filings

Seres Therapeutics, INC 8-K filings

NASDAQ
MCRB
Seres Therapeutics, INC
8-K: Seres Therapeutics Faces Default Notice Over Manufacturing Milestone Payment
Seres Therapeutics received a notice of default from its lender, Oaktree, due to a dispute over a milestone payment to Bacthera and related notification requirements.
NASDAQ
MCRB
Seres Therapeutics, INC
8-K: Seres Therapeutics Faces Nasdaq Delisting Notice Due to Low Share Price
Seres Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.
NASDAQ
MCRB
Seres Therapeutics, INC
8-K: Seres Therapeutics Increases Authorized Shares Following Annual Meeting
Seres Therapeutics' stockholders approved an increase in authorized common stock shares from 240 million to 360 million at the 2024 Annual Meeting.
NASDAQ
MCRB
Seres Therapeutics, INC
8-K: Seres Therapeutics Reports Q4 and Full Year 2023 Results, VOWST Sales Reach $19.6 Million Since Launch
Seres Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting $19.6 million in net sales for VOWST since its launch in June and providing updates on its clinical programs.
NASDAQ
MCRB
Seres Therapeutics, INC
8-K: Seres Therapeutics Appoints Marella Thorell as CFO, David Arkowitz to Retire
Seres Therapeutics has announced the appointment of Marella Thorell as its new Chief Financial Officer, succeeding David Arkowitz who will retire, effective March 15, 2024.
NASDAQ
MCRB
Seres Therapeutics, INC
8-K: Seres Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Seres Therapeutics has announced that its 2024 annual meeting of stockholders will be held on April 4, 2024, virtually.